{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=104", "query": { "condition": "Lymphoma", "page": 104 }, "page_size": 10 }, "pagination": { "page": 104, "page_size": 10, "total_count": 5760, "total_pages": 576, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=105&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=103&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T09:46:08.595Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00433537", "title": "Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Contiguous Stage II Mantle Cell Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Stage I Mantle Cell Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage IV Mantle Cell Lymphoma" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Autologous stem cell transplantation (ASCT)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2007-05", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2014-10-30", "last_synced_at": "2026-11-06T09:46:08.595Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00433537" }, { "nct_id": "NCT07225439", "title": "Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Hodgkin Lymphoma", "B-cell Non Hodgkin Lymphoma", "Diffuse Large B Cell Lymphoma", "High-grade B-cell Lymphoma", "Primary Mediastinal Large B Cell Lymphoma", "Follicular Lymphoma", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Marginal Zone Lymphoma", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Allogeneic NK cells", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Tafasitamab", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" }, { "name": "Fludarabine/cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Paolo Caimi, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2026-09", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-11-06T09:46:08.595Z", "location_count": 2, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07225439" }, { "nct_id": "NCT01592370", "title": "An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Hodgkin Lymphoma", "Multiple Myeloma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Lirilumab", "type": "BIOLOGICAL" }, { "name": "Daratumumab", "type": "BIOLOGICAL" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2012-08-02", "completion_date": "2024-07-09", "has_results": true, "last_update_posted_date": "2025-10-22", "last_synced_at": "2026-11-06T09:46:08.595Z", "location_count": 32, "location_summary": "Clovis, California • Los Angeles, California • Aurora, Colorado + 16 more", "locations": [ { "city": "Clovis", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01592370" }, { "nct_id": "NCT06074666", "title": "Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Lymphoblastic Leukemia, Pediatric" ], "interventions": [ { "name": "CareMeds Intervention", "type": "BEHAVIORAL" }, { "name": "Usual Care Group", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "9 Years", "sex": "ALL", "summary": "3 Years to 9 Years" }, "enrollment_count": 100, "start_date": "2024-11-07", "completion_date": "2027-10-01", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-11-06T09:46:08.595Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06074666" }, { "nct_id": "NCT07513129", "title": "Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "T-cell Acute Lymphoblastic Leukemia", "Lymphoma" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "12 Years to 30 Years" }, "enrollment_count": 18, "start_date": "2026-06-05", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-11-06T09:46:08.595Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07513129" }, { "nct_id": "NCT05705531", "title": "A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cardiovascular Disorder", "Classic Hodgkin Lymphoma", "Clonal Hematopoiesis" ], "interventions": [ { "name": "Archive Sample Retrieval", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Electronic Health Record Review", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": null, "sex": "ALL", "summary": "7 Years and older" }, "enrollment_count": 190, "start_date": "2023-08-18", "completion_date": "2028-10-01", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-11-06T09:46:08.595Z", "location_count": 35, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Duarte, California + 31 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Madera", "state": "California" }, { "city": "Hartford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05705531" }, { "nct_id": "NCT01339572", "title": "Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Multiple Myeloma" ], "interventions": [ { "name": "Plerixafor", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2011-04", "completion_date": "2015-11", "has_results": false, "last_update_posted_date": "2017-08-01", "last_synced_at": "2026-11-06T09:46:08.595Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01339572" }, { "nct_id": "NCT02793466", "title": "Durvalumab in Pediatric and Adolescent Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Lymphoma", "Central Nervous System Tumors" ], "interventions": [ { "name": "Durvalumab; MEDI4736", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Leo Mascarenhas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 15, "start_date": "2016-07", "completion_date": "2023-04-30", "has_results": false, "last_update_posted_date": "2023-09-22", "last_synced_at": "2026-11-06T09:46:08.595Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02793466" }, { "nct_id": "NCT02636322", "title": "Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma Unclassifiable" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2016-03-29", "completion_date": "2022-10-24", "has_results": true, "last_update_posted_date": "2024-03-13", "last_synced_at": "2026-11-06T09:46:08.595Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02636322" }, { "nct_id": "NCT06583395", "title": "Quest to Analyze One Thousand Humans Meditating", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Amyotrophic Lateral Sclerosis (ALS)", "Angina, Stable", "Anxiety", "Asthma", "Atrial Fibrillation", "Cancer Brain", "Cancer, Breast", "Cancer Colon", "Cancer, Lung", "Cancer, Ovarian", "Cancer Prostate", "Cancer Skin", "Throat Cancer", "Lymphoma", "Cancer, Thyroid", "Cancer, Other", "Cerebral Palsy", "Chronic Fatigue Syndrome", "Cluster Headache", "Chronic Obstructive Pulmonary Disease (COPD)", "Chronic Kidney Diseases", "Crohn Disease", "Deafness", "Depression", "Diabetes", "Eczema", "Epilepsy", "Fibroids", "Fibromyalgia", "Heart Failure", "Hypertension", "Hyperthyroidism", "Hypothyroidism", "Irritable Bowel Syndrome (IBS)", "Infertility", "Lyme Disease", "Macular Degeneration", "Migraine", "Multiple Allergies", "Multiple Sclerosis", "Osteoarthritis", "Osteoporosis", "Ovarian Cysts", "Parkinson Disease", "Phantom Limb Pain", "Psoriasis", "Post Traumatic Stress Disorder (PTSD)", "Rheumatoid Arthritis", "Sjogrens Disease", "Spinal Cord Injury", "Spinal Stenosis", "Stroke", "Tension Headache", "Tinnitus", "Ulcerative Colitis" ], "interventions": [ { "name": "Advanced multi-component meditation practice", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Tobias Moeller-Bertram", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 3000, "start_date": "2021-12-05", "completion_date": "2025-03-25", "has_results": false, "last_update_posted_date": "2024-11-01", "last_synced_at": "2026-11-06T09:46:08.595Z", "location_count": 1, "location_summary": "Palm Desert, California", "locations": [ { "city": "Palm Desert", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06583395" } ] }